ArticleCase reports in oncology
Severe Gastritis after Administration of Nivolumab and Ipilimumab.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- A systematic review of gastritis as an immune-related adverse event in clinical interventions.Human vaccines & immunotherapeutics · 2024Pooled it
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Guideline
- Nivolumab-Induced Refractory Hemorrhagic Gastritis and Duodenitis Requiring Multimodal Biologic Therapy.ACG case reports journal · 2025Article
- A case series of immune checkpoint inhibitor-induced gastritis.Contemporary oncology (Poznan, Poland) · 2025Article
- Managing immune checkpoint inhibitor-associated gastritis: Insights and strategies.World journal of gastroenterology · 2024Review
- Drug-induced mucosal alterations observed during esophagogastroduodenoscopy.World journal of gastroenterology · 2024Review
- Immune Checkpoint Inhibitor-Induced Hemorrhagic Gastritis.ACG case reports journal · 2023Article
- Drug-Associated Gastropathy: Diagnostic Criteria.Diagnostics (Basel, Switzerland) · 2023Review
- A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma.IJU case reports · 2023Article
- Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review.Endoscopy international open · 2022Article
- Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report.Clinical journal of gastroenterology · 2022Article
- Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection.ACG case reports journal · 2022Article
- Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.Frontiers in immunology · 2022Article
- Imaging features of toxicities associated with immune checkpoint inhibitors.European journal of radiology open · 2022Article
- A Case of Severe Acute Gastritis as an Immune-Related Adverse Event After Nivolumab Treatment: Endoscopic and Pathological Findings in Nivolumab-Related Gastritis.Digestive diseases and sciences · 2021Article
- Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry.Frontiers in oncology · 2021Article
- Gastrointestinal adverse events of immunotherapy.BJR open · 2021Review
- Severe gastritis due to pembrolizumab treatment in a lung cancer patient.Respirology case reports · 2020Article
- Severe steroid refractory gastritis induced by Nivolumab: A case report.World journal of gastroenterology · 2020Article
- Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.Current gastroenterology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies. As these inhibitors improve antitumor immunity via T-cell modulation, immune-mediated adverse events associated with T-cell activation, such as colitis, might occur. Herein, we describe a 75-year-old Japanese woman with metastatic malignant melanoma who developed hemorrhagic gastritis after ipilimumab treatment. There was no macroscopic or clinical improvement of gastritis after proton pump inhibitor treatment. However, her condition improved after approximately 3 weeks of corticosteroid therapy and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.